Different Effects of Eicosapentaenoic and Docosahexaenoic Acids on Atherogenic High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Mice.
Different Effects of Eicosapentaenoic and Docosahexaenoic Acids on Atherogenic High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Mice.
复制标题
DOI：
10.1371/journal.pone.0157580
复制
发表时间：
2016
期刊：
影响因子：
3.7
通讯作者：
Shimano H
中科院分区：
文献类型：
--
作者：
Suzuki-Kemuriyama N;Matsuzaka T;Kuba M;Ohno H;Han SI;Takeuchi Y;Isaka M;Kobayashi K;Iwasaki H;Yatoh S;Suzuki H;Miyajima K;Nakae D;Yahagi N;Nakagawa Y;Sone H;Yamada N;Shimano H
非酒精性脂肪性肝病（NAFLD）是代谢综合征的肝脏表现，可进展为脂肪性肝炎（NASH）和晚期肝损伤，如肝硬化和癌症。最近的研究表明，食用n-3多不饱和脂肪酸（PUFA）对治疗NAFLD有好处。在本研究中，我们调查并比较了主要的n-3 PUFA-二十碳五烯酸（EPA，C20：5）和二十二碳六烯酸（DHA，C22：6）-在预防致动脉粥样硬化高脂肪（AHF）饮食诱导的NAFLD中的作用。给小鼠喂食补充有或没有EPA或DHA的AHF饮食四周。EPA和DHA均降低了AHF饮食诱导的NASH病理学特征，如肝小叶炎症和血清转氨酶活性升高。有趣的是，EPA比DHA具有更大的肝脏三酰甘油（TG）降低作用。相比之下，DHA对AHF饮食诱导的肝脏炎症和ROS产生的抑制作用大于EPA，但在纤维化方面没有差异。EPA和DHA都可以有效治疗NAFLD和NASH。同时，两种主要的n-3多不饱和脂肪酸可能在向肝纤维化的病理中间步骤的相对贡献方面不同。
Non-alcoholic fatty liver disease (NAFLD), the hepatic manifestation of metabolic syndrome, can progress to steatohepatitis (NASH) and advanced liver damage, such as that from liver cirrhosis and cancer. Recent studies have shown the benefits of consuming n-3 polyunsaturated fatty acids (PUFAs) for the treatment of NAFLD. In the present study, we investigated and compared the effects of the major n-3 PUFAs—eicosapentaenoic acid (EPA, C20:5) and docosahexaenoic acid (DHA, C22:6)—in preventing atherogenic high-fat (AHF) diet-induced NAFLD. Mice were fed the AHF diet supplemented with or without EPA or DHA for four weeks. Both EPA and DHA reduced the pathological features of AHF diet-induced NASH pathologies such as hepatic lobular inflammation and elevated serum transaminase activity. Intriguingly, EPA had a greater hepatic triacylglycerol (TG)-reducing effect than DHA. In contrast, DHA had a greater suppressive effect than EPA on AHF diet-induced hepatic inflammation and ROS generation, but no difference in fibrosis. Both EPA and DHA could be effective for treatment of NAFLD and NASH. Meanwhile, the two major n-3 polyunsaturated fatty acids might differ in a relative contribution to pathological intermediate steps towards liver fibrosis.